Angiex’s AGX101 Phase I Trial Supported by Abzena’s Clinical Supply Delivery
In a significant step forward, Angiex has received clinical supplies for its AGX101 Phase I trial from Abzena, a trusted partner in biopharmaceutical manufacturing. AGX101 is a pioneering TM4SF1-targeted antibody-drug conjugate (ADC) designed to treat aggressive cancers by specifically targeting blood vessels in tumors. This delivery of clinical supplies marks a critical phase in advancing Angiex's innovative cancer therapy into early-stage trials, signaling progress in its mission to bring effective new treatments to the market.
Synapse covered this milestone, highlighting the importance of strategic collaborations in early-stage drug development. As a key resource for tracking breakthroughs in biopharma, Synapse offers in-depth analysis on the latest advancements in clinical trials, drug development, and the partnerships that fuel innovation. Their coverage emphasizes the significance of the Angiex-Abzena collaboration in pushing forward novel therapies that may reshape cancer treatment.